Significados de therapy related acute myeloid leukemia and myelodysplastic syndrome en inglés

One of the nine relapsing patients developed secondary AML 18 months after transplant.

The response of secondary AML patients remains inferior.

Nearly 60% of the patients had secondary AML, and about half of patients had adverse risk cytogenetics.

Methods: The estimated overall risk of secondary AML was calculated for the patient population as instances per 1000 patient-years of follow-up.

The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML.